Since 1998, OCRF has awarded 217 grants totaling over $57 million for ovarian cancer research to top scientists at more than 60 leading medical centers. We invest our dollars wisely, supporting the best ovarian cancer research in the nation.
OCRF-funded projects have led to significant advances in such areas as early detection, diagnosis, genetics, prevention, treatments, and enhancing quality of life. In just the past year, OCRF funded researchers have:
- Discovered that analyzing data from pap smears could help detect endometrial and ovarian cancer
- Shown that there is no link between obesity and risk for the most common type of ovarian cancer
- Found that a subset of immune cells promote tumor growth
- Demonstrated that evaluating the change of CA-125 over time shows promise as a screening tool for early stage ovarian cancer
- Helped clarify which cell lines are the best fit for use in ovarian cancer research
- Found similarities between some endometrial, breast and ovarian cancers
- Showed how an experimental drug may be helpful in fighting platinum-resistant ovarian cancer
- Shown that combining targeted agents is effective against ovarian cancer
- Shed light on the origins of ovarian cancer in BRCA mutation carriers
The results of OCRF-supported research projects have been published in some of the world’s most prestigious journals, such as: Gynecologic Oncology, Lancet Oncology, New England Journal of Medicine, Cancer Research, Clinical Cancer Research, Journal of Clinical Oncology, Science Translational Medicine, Cancer Discovery and Nature.